All In Biotech

Drugs by condition

Drugs approved for uterine fibroids

Brand-name prescription drugs and biologics whose FDA label lists uterine fibroids as an approved use. Matched on the label phrases: "uterine fibroids", "uterine leiomyomas".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

2

Still marketed, NDA or BLA

Drug classes

2

Novel drugs

0

New molecular entities and new biologics

In development

1

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for uterine fibroids.

  • Myfembree (Estradiol, Norethindrone Acetate, Relugolix) · Sumitomo Pharma Am May 26, 2021
  • Oriahnn (Copackaged) (Elagolix Sodium,Estradiol,Norethindrone Acetate, Elagolix Sodium) · Abbvie May 29, 2020

All approved drugs for uterine fibroids, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 7 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Gonadotropin Releasing Hormone Receptor Antagonist (1)

  • Myfembree Estradiol, Norethindrone Acetate, Relugolix · Sumitomo Pharma Am · 2021

Class not listed in FDA's data (1)

  • Oriahnn (Copackaged) Elagolix Sodium,Estradiol,Norethindrone Acetate, Elagolix Sodium · Abbvie · 2020

Drugs in development for uterine fibroids

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • KLH-2109Phase 32 trials

    JW Pharmaceutical · Menorrhagia, Uterine Fibroids, Endometriosis

More on uterine fibroids: recruiting trials · published research

Related in endocrinology and women's health: Hypothyroidism · Osteoporosis · Menopause symptoms · Endometriosis · Birth control · Low testosterone · Growth hormone deficiency · Acromegaly · Cushing's syndrome

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.